National Use of Postmenopausal Hormone Therapy: Annual Trends and Response to Recent Evidence

JAMA

Volumn 291, Issue 1, 2004, Pages 47-53

  Hersh, Adam L ^a   Stefanick, Marcia L ^a   Stafford, Randall S ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONJUGATED ESTROGEN; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; ESTROGEN; GESTAGEN;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL PRACTICE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA BASE; DOSE RESPONSE; DRUG FORMULATION; FEMALE; GYNECOLOGY; HORMONE SUBSTITUTION; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MENOPAUSAL SYNDROME; OBSTETRICS; POSTMENOPAUSE OSTEOPOROSIS; PRESCRIPTION; PRIORITY JOURNAL; SIDE EFFECT;

EID: 0346599193     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.291.1.47     Document Type: Article

References (33)

1. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA. 1998;280:605-613.
2. Grady D, Herrington D, Bittner V, et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy. JAMA. 2002;288:49-57.
3. Writing Group for the Women's Health Initiative Investigators. Risk and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health initiative randomized controlled trial. JAMA. 2002;288:321-333.
4. Grodstein F, Manson JE, Colditz GA, et al. A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med. 2000;133:933-941.
5. Barrett-Connor E, Grady D. Hormone replacement therapy, heart disease, and other considerations. Annu Rev Public Health. 1998;19:55-72.
6. Grady D, Rubin SM, Petitti DB, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med. 1992;117:1016-1037.
7. US Preventive Services Task Force. Postmenopausal hormone replacement therapy for primary prevention of chronic conditions: recommendations and rationale. Ann Intern Med. 2002;137:834-839.
8. Nelson HD. Assessing benefits and harms of hormone replacement therapy. JAMA. 2002;288:882-884.
9. Solomon CG, Dluhy RG. Rethinking postmenopausal hormone therapy. N Engl J Med. 2003;348:579-580.
10. Wysowski Dk, Golden L, Burke L. Use of menopausal estrogens and medroxyprogesterone in the United States, 1982-1992. Obstet Gynecol. 1995;85:6-10.
11. Kennedy DL, Baum C, Forbes MB. Noncontraceptvie estrogens and prgestins: use patterns over time. Obstet Gynecol. 1985;65:441-446.
12. Hemminki E, Kennedy DL, Baum C, McKinlay SM. Prescribing of noncontraceptive estrogens and progestins in the United States, 1974-86. Am J Public Health. 1988;78:1478-1481.
13. Keating NL, Cleary PD, Rossi AS, et al. Use of hormone replacement therapy by postmenopausal women in the United States. Ann Intern Med. 1999;130:545-553.
14. Whitlock EP, Johnson RE, Vogt TM. Recent patterns of hormone replacement therapy use in a large managed care organization. J Womens Health. 1998;7:1017-1026.
15. Majumdar SR, Inui TS, Gurwitz JH, et al. Influence of physician specialty on adoption and relinquishment of calcium channel blockers and other treatments for myocardial infarction. J Gen Intern Med. 2001;16:351-359.
16. Maclure M, Dormuth C, Nauman T, et al. Influence of educational interventions and adverse news about calcium-channel blockers on first-line prescribing of antihypertensive drugs to elderly people in British Columbia. Lancet. 1998;352:943-948.
17. Stafford RS, Drieling R, Hersh AL. National trends in osteoporosis visits and osteoporosis treatment, 1988-2003. Arch Intern Med. In press.
18. Herrington DM, Reboussin DM, Brosnihan B, et al. Effects of estrogen replacement on the progression of coronary artery atherosclerosis. N Engl J Med. 2000;343:522-529.
19. Viscoli CM, Brass LM, Kernan WN, et al. A clinical trial of estrogen-replacement therapy after ischemic stroke. N Engl J Med. 2001;345:1243-1249.
20. Lenfant C. Preliminary Trends in the Women's Health Initiative [Press release]. Bethesda, Md: National Heart, Lung, and Blood Institute; March 24, 2000.
21. WHI (Women's Health Initiative) HRT Update 2001. Available at: http://www.nhlbi.nih.gov/whi. Accessibility verified December 5, 2003.
22. Mosca L, Collins P, Herrington DM, et al. Hormone replacement therapy and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation. 2001;104:499-503.
23. Erblich J, Bovbjerg DH, Norma C, et al. It won't happen to me: lower perception of heart disease risk among women with family histories of breast cancer. Prev Med. 2000;31:714-721.
24. Black WC, Nease RF Jr, Tosteson AN. Perceptions of breast cancer risk and screening effectiveness in women younger than 50 years of age. J Natl Cancer Inst. 1995;87:720-731.
25. Shumaker SA, Legault C, Rapp SR, et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal Women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA. 2003;289:2651-2662.
26. Rapp SR, Espeland MA, Shumaker SA, et al. Effect of estrogen plus progestin on global cognitive function in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA. 2003;289:2663-2672.
27. Ascott-Evans BH, Guanabens N, Kivinen S, et al. Alendronate prevents loss of bone density associated with discontinuation of hormone replacement therapy: a randomized controlled trial. Arch Intern Med. 2003;163:789-794.
28. Manson JE, Hsia J, Johnson KC, et al, for the Women's Health Initiative Investigators. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med. 2003;349:523-534.
29. Chlebowski RT, Hendrix SL, Langer RD, et al, for the WHI Investigators. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative randomized trial. JAMA. 2003;289:3243-3253.
30. Wassertheil-Smoller S, Hendrix SL, Limacher M, et al, for the WHI Investigators. Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: a randomized trial. JAMA. 2003;289:2673-2684.
31. Grodstein F, Stampfer MJ, Colditz GA, et al. Postmenopausal hormone therapy and mortality. N Engl J Med. 1997;336:1679, 1769-1775.
32. US Census Bureau, Population Division. Resident Population Estimates of the United States by Age and Sex: April 1, 1990 to July 1, 1999, with Short-Term Projection to November 1, 2000. Available at: http://eire.census.gov/popest/archives/national/nation2/intfile2-1.txt. Accessibility verified November 26, 2003.
33. US Census Bureau, Population Division. Resident Population Estimates of the United States by Age and Sex: April 1, 2000, July 1, 2000 and July 1, 2001. Available at: http://eire.census.gov/popest/data /national/tables/asro/US-EST2001-ASRO-O1.php.